Osteoarthritis Treatment Market to Witness Robust Growth in North America & Europe

The increasing incidence of osteoarthritis around the world is major factor driving the growth of the osteoarthritis treatment market. Osteoarthritis (OA) is one of the most prevalent chronic diseases across the globe. According to the Centers for Disease Control and Prevention (CDC), OA affects over 32.5 million Americans. Osteoarthritis is the most common form of arthritis. The projected prevalence of US adults who will report doctor-diagnosed arthritis, by year: 63 million by 2020, 67 million by 2025, 72 million by 2030, 75 million by 2035, and 78 million by 2045. Thus, with the increasing incidence of osteoarthritis, the demand for osteoarthritis treatment is also increasing, driving the osteoarthritis treatment market growth.

Sample Copy Of Report @ https://www.coherentmarketinsights.com/insight/request-sample/915

Osteoarthritis treatment includes medication, physiotherapy, and sometimes surgery to reduce pain and maintain joint movement. Over-the-counter drugs and nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen sodium and ibuprofen taken at the recommended doses, are extensively used to relieve pain in osteoarthritis patients. In the United States, more than 50% of osteoarthritis patients were prescribed with NSAIDs, according to the 2019 report by the National Center for Biotechnology Information. Similarly, in Europe, of the total number of osteoarthritis patients using prescription drugs (47%), around 60% received NSAIDs. This in turn is also expected to augment the growth of the osteoarthritis treatment market.

Osteoporosis is the most common age-linked bone disease across the world. The disorder most commonly affects joints in spine, hips, knees, and hands. It is a leading cause of disability worldwide, and thus, there is an increasing demand for osteoarthritis treatment. For instance, in October 2019, in support of World Arthritis Day, Bioventus launched a disease and product information website called OAKneePainRelief.com which combines information on knee osteoarthritis (OA) for both patients and health care providers (HCPs) with the full Bioventus portfolio of hyaluronic acid-based joint-fluid treatment options. The aforementioned factors are expected to accelerate the osteoarthritis treatment market growth.

Over-the-counter drugs and NSAIDs are widely used to relieve pain in osteoarthritis patients. Topical NSAIDs are recommended as a well-tolerated, guideline-supported, and effective first-line treatment option for knee & hand osteoarthritis especially for older patients. Therefore, with increasing geriatric population, the demand for osteoarthritis treatment is also increasing, driving the market growth. OA is the leading cause of disability in individuals older than 65 years and affects 70% to 90% of those older than 75 years. However, there are some major factors that may inhibit the growth of osteoarthritis treatment market, such as side effects of available therapeutics and the high cost of hyaluronic acid-based products. Some common side effects include dry mouth, nausea, constipation, and sleepiness.

Major Players Are: Johnson & Johnson Ltd., Abbott Laboratories, Pfizer, Inc., Novartis AG, Eli Lily and Co., Abiogen Pharma, Ampio Pharmaceuticals, Halyard Health, and BioDelivery Sciences International, Inc.

Buy Now with Discount for Premium Report : https://www.coherentmarketinsights.com/promo/buynow/915

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.